title: SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.
abstract: OBJECTIVE
  Androgen deprivation therapy (ADT), an important treatment for advanced prostate cancer, is highly variable in its effectiveness. We hypothesized that genetic variants of androgen transporter genes, SLCO2B1 and SLCO1B3, may determine time to progression on ADT.
  
  
  METHODS
  A cohort of 538 patients with prostate cancer treated with ADT was genotyped for SLCO2B1 and SLCO1B3 single nucleotide polymorphisms (SNP). The biologic function of a SLCO2B1 coding SNP in transporting androgen was examined through biochemical assays.
  
  
  RESULTS
  Three SNPs in SLCO2B1 were associated with time to progression (TTP) on ADT (P < .05). The differences in median TTP for each of these polymorphisms were about 10 months. The SLCO2B1 genotype, which allows more efficient import of androgen, enhances cell growth and is associated with a shorter TTP on ADT. Patients carrying both SLCO2B1 and SLCO1B3 genotypes, which import androgens more efficiently, exhibited a median 2-year shorter TTP on ADT, demonstrating a gene-gene interaction (P(interaction) = .041).
  
  
  CONCLUSIONS
  Genetic variants of SLCO2B1 and SLCO1B3 may function as pharmacogenomic determinants of resistance to ADT in prostate cancer.
authors: Dana-Farber Cancer Institute, Harvard Medical School, Dana 710B, 44 Binney St., Boston, MA 02115, USA. gwo-shu_lee@dfci.harvard.edu
authors: Ming
authors: M
authors: Yang
authors: Wanling
authors: W
authors: Xie
authors: Elahe
authors: E
authors: Mostaghel
authors: Mari
authors: M
authors: Nakabayashi
authors: Lillian
authors: L
authors: Werner
authors: Tong
authors: T
authors: Sun
authors: Mark
authors: M
authors: Pomerantz
authors: Matthew
authors: M
authors: Freedman
authors: Robert
authors: R
authors: Ross
authors: Meredith
authors: M
authors: Regan
authors: Nima
authors: N
authors: Sharifi
authors: William Douglas
authors: WD
authors: Figg
authors: Steven
authors: S
authors: Balk
authors: Myles
authors: M
authors: Brown
authors: Mary-Ellen
authors: ME
authors: Taplin
authors: William K
authors: WK
authors: Oh
authors: Gwo-Shu Mary
authors: GS
authors: Lee
authors: Philip W
authors: PW
authors: Kantoff
references: Naunyn Schmiedebergs Arch Pharmacol. 2006 Mar;372(6):432-43
references: 16525793
references: J Urol. 1984 Oct;132(4):693-6
references: 6471215
references: Clin Cancer Res. 2004 Nov 1;10(21):7121-6
references: 15534082
references: Cancer Res. 2008 Jun 1;68(11):4447-54
references: 18519708
references: Pflugers Arch. 2004 Feb;447(5):653-65
references: 14579113
references: Nat Genet. 2006 Nov;38(11):1298-303
references: 17057720
references: N Engl J Med. 2003 Jul 24;349(4):366-81
references: 12878745
references: J Clin Endocrinol Metab. 2003 Aug;88(8):3902-12
references: 12915686
references: Nat Rev Cancer. 2001 Oct;1(1):34-45
references: 11900250
references: Clin Cancer Res. 2005 Jul 1;11(13):4653-7
references: 16000557
references: Cancer Res. 2006 Mar 1;66(5):2815-25
references: 16510604
references: J Clin Oncol. 2002 Jul 1;20(13):3001-15
references: 12089231
references: BJU Int. 2008 Aug 5;102(5):617-21
references: 18537956
references: Clin Cancer Res. 2009 May 15;15(10):3251-5
references: 19447877
references: Cancer. 2008 Mar 15;112(6):1247-53
references: 18293426
references: Mol Cell. 2005 Sep 2;19(5):631-42
references: 16137620
references: J Steroid Biochem. 1989 Aug;33(2):195-200
references: 2475673
references: Nat Rev Drug Discov. 2010 Mar;9(3):215-36
references: 20190787
references: Steroids. 1998 May-Jun;63(5-6):322-8
references: 9618795
references: Pharmacogenetics. 2004 Jul;14(7):441-52
references: 15226676
references: J Clin Oncol. 2008 Feb 20;26(6):842-7
references: 18281655
references: Clin Cancer Res. 2006 Mar 15;12(6):1665-71
references: 16551847
references: Clin Cancer Res. 2008 Jun 1;14(11):3312-8
references: 18519758
references: Clin Genitourin Cancer. 2006 Jun;5(1):61-6
references: 16859581
references: Expert Opin Drug Metab Toxicol. 2005 Oct;1(3):429-45
references: 16863454
references: J Clin Oncol. 2005 Nov 10;23(32):8253-61
references: 16278481
references: Pharmacogenet Genomics. 2009 Feb;19(2):129-38
references: 19151602
references: Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60
references: 10873595
references: Am J Clin Oncol. 1988;11 Suppl 2:S30-6
references: 2853935
references: J Pharmacol Exp Ther. 2002 Aug;302(2):804-13
references: 12130747
references: J Clin Endocrinol Metab. 1994 Oct;79(4):1086-90
references: 7962278
references: Mol Endocrinol. 1993 Dec;7(12):1541-50
references: 8145761